Unity Biotechnology, Inc. Common Stock
UBX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
UBX Income Statement
UBX Balance Sheet
UBX Cash Flow
Recent trades of UBX by members of U.S. Congress
UBX Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
UBX Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
UBX Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by UBX's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Methods of treating retinal vasculopathies Apr. 09, 2024
-
Patent Title: Methods of inhibiting pathological angiogenesis Jan. 09, 2024
-
Patent Title: Methods of inhibiting pathological angiogenesis Sep. 28, 2021
-
Patent Title: Acylsulfonamide derivatives for treating senescence-associated diseases and disorders Sep. 07, 2021
-
Patent Title: Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Apr. 20, 2021
-
Patent Title: Conjugates that are configured for targeted delivery of therapeutic compounds to senescent cells Aug. 18, 2020
-
Patent Title: Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Aug. 18, 2020
-
Patent Title: Phosphonamidates that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Aug. 11, 2020
-
Patent Title: Acyl sulfonamides that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Jul. 21, 2020
-
Patent Title: Acyl phosphonamidates and acyl benzylamines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer Jul. 07, 2020
-
Patent Title: Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer Jun. 23, 2020
-
Patent Title: Technology to inhibit vascular changes that lead to vision loss in the eye Mar. 17, 2020
-
Patent Title: Composition comprising a gene vector that selectively depletes p16 positive senescent cells Feb. 04, 2020
-
Patent Title: Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer Dec. 31, 2019
-
Patent Title: Removing senescent cells from a mixed cell population or tissue using a phosphoinositide 3-kinase (pi3k) inhibitor Dec. 31, 2019
-
Patent Title: Unit dose of an aryl sulfonamide that is effective for treating eye disease and averting potential vision loss Nov. 19, 2019
-
Patent Title: Compositions of matter for treatment of ophthalmic conditions by selectively removing senescent cells from the eye Nov. 19, 2019
-
Patent Title: Chemical entities that kill senescent cells for use in treating age-related disease Oct. 01, 2019
-
Patent Title: Replication conditional virus that specifically kills senescent cells Aug. 13, 2019
-
Patent Title: Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use Jun. 25, 2019
-
Patent Title: Use of sulfonamide inhibitors of bcl-2 and bcl-xl to treat ophthalmic disease by selectively removing senescent cells Jun. 25, 2019
-
Patent Title: Immunogenic compositions for inducing an immune response for elimination of senescent cells May. 07, 2019
-
Patent Title: Treating pulmonary conditions by selectively removing senescent cells from the lung using an intermittent dosing regimen Apr. 16, 2019
-
Patent Title: Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population Feb. 26, 2019
-
Patent Title: Chemical entities that kill senescent cells for use in treating age-related disease Feb. 05, 2019
-
Patent Title: Treatment of joint pain Nov. 20, 2018
-
Patent Title: Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Jul. 03, 2018
-
Patent Title: Treatment for osteoarthritis in a joint by administering a means for inhibiting mdm2 Jun. 12, 2018
-
Patent Title: Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use Jun. 05, 2018
-
Patent Title: Use of sulfonamide inhibitors of bcl-2 to treat senescence-associated lung conditions such as pulmonary fibrosis and chronic obstructive pulmonary disease May. 29, 2018
-
Patent Title: Drug conjugates for delivering compounds to senescent cells May. 15, 2018
-
Patent Title: Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline Jan. 02, 2018
-
Patent Title: Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells Dec. 26, 2017
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of UBX in WallStreetBets Daily Discussion
UBX News
Recent insights relating to UBX
CNBC Recommendations
Recent picks made for UBX stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in UBX
UBX Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view UBX Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More